on Jaguar Health, Inc. (NASDAQ:JAGX)
Ladenburg Thalmann to Host Scientific Showcase on Jaguar Health's Crofelemer
Ladenburg Thalmann will host a virtual Scientific Showcase on December 18, 2024, dedicated to clinical development efforts for Jaguar Health's Crofelemer. This event will examine Crofelemer, a plant-based anti-diarrheal drug, with a focus on rare diseases like microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF). Currently, five clinical initiatives are in progress across different regions, including the US and Europe. Significant proof-of-concept results are anticipated by Q2 2025.
The event will feature insights from Jaguar Health's leadership, including CEO Lisa Conte and Chief Scientific Officer Pravin Chaturvedi. Registration for this event, aimed at the financial and business community, is now open. Jaguar Health's efforts in expanding Crofelemer access in Europe were recently recognized, with Massimo Radaelli, CEO of Jaguar's Napo Therapeutics, receiving industry accolades.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Jaguar Health, Inc. news